Suppressor of Cytokine Signaling 3: Emerging Role Linking Central Insulin Resistance and Alzheimer’s Disease
Open Access
- 20 June 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Neuroscience
- Vol. 12, 417
Abstract
Currently, the aetiology of Alzheimer’s disease (AD) is still elusive. Central insulin resistance has been determined to play an important role in the progress of AD. However, the mechanism underlying the development of disrupted insulin signalling pathways in AD is unclear. Suppressor of cytokine signalling 3 (SOCS3) is a member of the SOCS protein family that acts as a negative modulator of insulin signalling in sensitive tissues, such as hepatocytes and adipocytes. However, little is known about its role in neurological diseases. Recent evidence indicates that the level of SOCS3 is increased in the brains of individuals with AD, especially in areas with amyloid beta (Aβ) deposition, suggesting that SOCS3 may regulate the central insulin signalling pathways in AD. Here, we discuss the potential role of SOCS3 in AD and speculate that SOCS3 may be a promising therapeutic target for the treatment of AD.Keywords
Funding Information
- National Natural Science Foundation of China (81701056)
- Science and Technology Commission of Shanghai Municipality (20164Y0193, 20174Y0168)
This publication has 89 references indexed in Scilit:
- The immunology of neurodegenerationJournal of Clinical Investigation, 2012
- An anti-diabetes agent protects the mouse brain from defective insulin signaling caused by Alzheimer’s disease–associated Aβ oligomersJournal of Clinical Investigation, 2012
- Demonstrated brain insulin resistance in Alzheimer’s disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive declineJournal of Clinical Investigation, 2012
- Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive ImpairmentArchives of Neurology, 2012
- Resveratrol mitigates lipopolysaccharide‐ and Aβ‐mediated microglial inflammation by inhibiting the TLR4/NF‐κB/STAT signaling cascadeJournal of Neurochemistry, 2011
- Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Aβ deposition in an Alzheimer mouse model with diabetesProceedings of the National Academy of Sciences, 2010
- SOCS3 Deletion Promotes Optic Nerve Regeneration In VivoNeuron, 2009
- Antidiabetic drug metformin (Glucophage R ) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcriptionProceedings of the National Academy of Sciences, 2009
- Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2008
- Structure of the SOCS4-ElonginB/C Complex Reveals a Distinct SOCS Box Interface and the Molecular Basis for SOCS-Dependent EGFR DegradationStructure, 2007